Begins research collaboration with the University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust in the UK

VibroSense Dynamics AB (publ) has signed a tripartite research agreement with the University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust to run a study beginning January 2026 that will use the VibroSense Meter® II to evaluate a Closed Loop treatment for painful diabetic neuropathy (pDPN) and to identify likely responders. The collaboration aims to validate the VibroSense Meter II as a superior point-of-care diagnostic and, if treatment effects are positive, to position the device as a standard tool for diabetic foot checks—potentially opening a large addressable market given global diabetes prevalence (≈589 million) and high rates of peripheral neuropathy/pDPN cited in epidemiological reviews.

Analysis

Market structure: a positive readout for VibroSense’s Meter II would directly benefit niche diagnostic vendors and neurostimulation device makers (higher referral rates for closed‑loop neuromodulation) while pressuring low‑accuracy point‑of‑care screening providers. The global addressable pool is large (≈589M people with diabetes; if ~50% develop DPN and ~46.7% of those have pDPN, the symptomatic addressable population is on the order of 100–150M), but commercial adoption is likely gradual (3–7 years) and concentrated in specialist clinics, so winners are likely concentrated, not broad‑based.

Risk assessment: tail risks include a negative trial (clinical futility), payer rejection of reimbursement, or technical failure to outperform cheaper alternatives — any of which could wipe out premiums in small‑cap valuations (≥50% downside). Near term (days–months) market impact is minimal; key timelines are study start Jan 2026, interim signals 12–24 months, and real‑world adoption 3+ years. Hidden dependencies: clinician economics, NICE/HCPCS codes, and competing wearable/AI diagnostics.

Trade implications: tactically favor large-cap device exposure (Medtronic MDT, Boston Scientific BSX, Abbott ABT) and selective small‑cap/ETF plays in diagnostics (IHI) while keeping positions modest (1–3% NAV) and using defined‑risk option structures (3–12 month call spreads). If VibroSense is listed, consider a small speculative position ahead of Jan 2026 with a deep stop; allocate capital to capture asymmetric upside from a positive validation.

Contrarian angles: consensus may overestimate speed of clinical adoption and reimbursement; a statistically significant but clinically small effect (e.g., <20–30% incremental responder rate) likely won’t move payers or procurement. Historical parallels (other diagnostics that showed accuracy but failed commercial uptake) counsel sizing positions conservatively and demanding hard-effect thresholds and payer signals before scaling exposure.

Key Decisions for Investors

• Establish a 1–2% NAV long in Medtronic (MDT) over the next 30 days to gain exposure to potential increased neurostimulation demand; set a 12‑month target of +12–18% and a hard stop at -10%.
• Initiate a tactical 0.5–1% NAV buy of a 3–9 month call spread on Boston Scientific (BSX) (buy ~5% OTM / sell ~20% OTM) to capture upside if closed‑loop therapies accelerate; exit on 25% realized P/L or at expiration.
• If VibroSense Dynamics is publicly tradable, accumulate a speculative 0.5–1% NAV position ahead of the Jan 2026 study start; predefine a stop-loss at -40% and trim 50% on any positive interim proof‑of‑concept signal within 12–24 months.
• Rotate 2–3% NAV from high‑multiple diabetes pharma (e.g., NVO) into the iShares U.S. Medical Devices ETF (IHI) over the next 90 days to express conviction in device/diagnostic re‑rating; reassess after the first interim readout (expected within 12–24 months).
• Monitor three binary catalysts precisely: (1) study initiation confirmation Jan 2026, (2) first interim efficacy signal by mid‑2026–2027, and (3) payer/reimbursement guidance (NICE/HCPCS) — if any fail, reduce small‑cap diagnostics exposure by 50% within 2 weeks.